Haggai Bar-Yoseph1,2, Shaqed Carasso3, Shlomit Shklar4, Alexander Korytny1, Razi Even Dar5, Haneen Daoud5, Roni Nassar1, Nitsan Maharshak6, Khetam Hussein4, Yuval Geffen7, Yehuda Chowers1,8, Naama Geva-Zatorsky3,9, Mical Paul2,4. 1. Department of Gastroenterology, Rambam Health Care Campus, Haifa, Israel. 2. Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel. 3. Department of Cell Biology and Cancer Science, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Technion Integrated Cancer Center, Haifa, Israel. 4. Division of Infectious Disease, Rambam Health Care Campus, Haifa, Israel. 5. Department of Internal Medicine H, Rambam Health Care Campus, Haifa, Israel. 6. Bacteriotherapy Clinic, Department of Gastroenterology and Liver Diseases, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel (affiliated with the Sackler Faculty of Medicine, Tel Aviv University). 7. Microbiology Laboratory, Rambam Health Care Campus, Haifa, Israel. 8. Clinical Research Institute, Rambam Health Care Campus, Haifa, Israel. 9. Canadian Institute for Advanced Research, MaRS Centre, Toronto, Ontario, Canada.
Abstract
BACKGROUND: Carbapenemase-producing Enterobacteriaceae (CPE) infections lead to considerable morbidity and mortality. We assessed the potential of fecal microbiota transplantation (FMT) to eradicate CPE carriage and aimed to explain failure or success through microbiome analyses. METHODS: In this prospective cohort study, all consenting eligible CPE carriers received oral capsulized FMT for 2 days. Primary outcome was CPE eradication at 1 month, defined by 3 consecutive negative rectal swabs, the last also negative for carbapenemase gene by polymerase chain reaction. Comprehensive metagenomics analysis of the intestinal microbiome of donors and recipients before and after FMT was performed. RESULTS: Fifteen CPE carriers received FMT, 13 of whom completed 2 days of treatment. CPE eradication at 1 month was successful in 9/15 and 9/13, respectively. Bacterial communities showed significant changes in both beta and alpha diversity metrics among participants who achieved CPE eradication that were not observed among failures. Post-FMT samples' beta-diversity clustered according to the treatment outcome, both in taxonomy and in function. We observed a significant decrease in beta diversity in participants who received post-FMT antibiotics. Enterobacteriaceae abundance decreased in post-FMT samples of the responders but increased among failures. Functionally, a clear demarcation between responders (who were similar to the donors) and failures was shown, driven by antimicrobial resistance genes. CONCLUSIONS: Our study provides the biological explanation for the effect of FMT against CPE carriage. Decolonization of CPE by FMT is likely mediated by compositional and functional shifts in the microbiome. Thus, FMT might be an efficient strategy for sustained CPE eradication. CLINICAL TRIALS REGISTRATION: NCT03167398.
BACKGROUND: Carbapenemase-producing Enterobacteriaceae (CPE) infections lead to considerable morbidity and mortality. We assessed the potential of fecal microbiota transplantation (FMT) to eradicate CPE carriage and aimed to explain failure or success through microbiome analyses. METHODS: In this prospective cohort study, all consenting eligible CPE carriers received oral capsulized FMT for 2 days. Primary outcome was CPE eradication at 1 month, defined by 3 consecutive negative rectal swabs, the last also negative for carbapenemase gene by polymerase chain reaction. Comprehensive metagenomics analysis of the intestinal microbiome of donors and recipients before and after FMT was performed. RESULTS: Fifteen CPE carriers received FMT, 13 of whom completed 2 days of treatment. CPE eradication at 1 month was successful in 9/15 and 9/13, respectively. Bacterial communities showed significant changes in both beta and alpha diversity metrics among participants who achieved CPE eradication that were not observed among failures. Post-FMT samples' beta-diversity clustered according to the treatment outcome, both in taxonomy and in function. We observed a significant decrease in beta diversity in participants who received post-FMT antibiotics. Enterobacteriaceae abundance decreased in post-FMT samples of the responders but increased among failures. Functionally, a clear demarcation between responders (who were similar to the donors) and failures was shown, driven by antimicrobial resistance genes. CONCLUSIONS: Our study provides the biological explanation for the effect of FMT against CPE carriage. Decolonization of CPE by FMT is likely mediated by compositional and functional shifts in the microbiome. Thus, FMT might be an efficient strategy for sustained CPE eradication. CLINICAL TRIALS REGISTRATION: NCT03167398.
Authors: Qin Liu; Tao Zuo; Wenqi Lu; Yun Kit Yeoh; Qi Su; Zhilu Xu; Whitney Tang; Keli Yang; Fen Zhang; Louis H S Lau; Rashid N S Lui; Miu Ling Chin; Rity Wong; Chun Pan Cheung; Wenyi Zhu; Paul K S Chan; Francis K L Chan; Grace C Lui; Siew C Ng Journal: mSystems Date: 2022-06-01 Impact factor: 7.324
Authors: Frederik Cold; Simon Mark Dahl Baunwall; Jens Frederik Dahlerup; Andreas Munk Petersen; Christian Lodberg Hvas; Lars Hestbjerg Hansen Journal: Therap Adv Gastroenterol Date: 2021-08-31 Impact factor: 4.409
Authors: Andrew J Innes; Benjamin H Mullish; Rohma Ghani; Richard M Szydlo; Jane F Apperley; Eduardo Olavarria; Renuka Palanicawandar; Edward J Kanfer; Dragana Milojkovic; Julie A K McDonald; Eimear T Brannigan; Mark R Thursz; Horace R T Williams; Frances J Davies; Julian R Marchesi; Jiří Pavlů Journal: Front Cell Infect Microbiol Date: 2021-08-27 Impact factor: 5.293
Authors: Elena Pérez-Nadales; Ángela Cano; Manuel Recio; María José Artacho; Julia Guzmán-Puche; Antonio Doblas; Elisa Vidal; Clara Natera; Luis Martínez-Martínez; Julian Torre-Cisneros; Juan José Castón Journal: BMJ Open Date: 2022-04-06 Impact factor: 2.692
Authors: Daniel Podlesny; Marija Durdevic; Sudarshan Paramsothy; Nadeem O Kaakoush; Christoph Högenauer; Gregor Gorkiewicz; Jens Walter; W Florian Fricke Journal: Cell Rep Med Date: 2022-08-04